No Data
No Data
Telomir Pharmaceuticals Added to Membership of Russell 3000 and Russell Microcap Indexes
TAMPA, Fla., July 02, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of
Telomir Pharmaceuticals Scientific Advisor to Participate in Drug Information Association 2024 Global Annual Meeting Panel
TAMPA, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of
Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1
Commences the study, The Safety of Telomir-1 when Administered Orally to Geriatric Laboratory Beagle Dogs for 63 Consecutive Days study to evaluate the safety of Telomir-1 on geriatric canines Began geriatric canine
New to The Street TV Announces Episode 575 With Its Four Business Guest Interviews, Airs as Sponsored Programming on Bloomberg TV, Saturday, May 25, 2024, at 6:30 PM ET
NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) -- FMW Media's New to The Street announces broadcasting of its national business show that will air as a sponsored program on Bloomberg TV on Saturday, May 25, 2024, at 6:30
Telomir Pharmaceuticals, Inc. Signs Media Deal With New to The Street for Network Interview Broadcasts, Billboards, and TV Commercial Support
NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- FMW Media Works' New to The Street televised business show will feature Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ($TELO) ("Company"), a pre-clinical stage
Telomir Pharmaceuticals | 10-Q: Quarterly report
No Data